Drugs / fluorine F 18 fluorothymidine
fluorine F 18 fluorothymidine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01825902 | Mar 2013 → Jan 2014 | Ewing sarcoma of bone, extraskeletal Ewing sarcoma, supratentorial primitive neuroectodermal tumor | Mayo Clinic | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT00880074 | Apr 2009 → Feb 2022 | cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fluorine F 18 fluorothymidine | “Undergo fluorine F-18 fluorothymidine PET” NCT00880074 ↗ |
| Modality | Diagnostic / imaging agent | “18F-FLT positron emission tomography” NCT01825902 ↗ |